Are Semaglutides Safe? The Evidence-Based Answer for Weight Loss and Diabetes Patients

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide has an 8-year safety track record from clinical trials involving over 17,000 patients, with serious adverse events occurring in fewer than 2% of participants across all major studies
• The most common side effects (nausea, vomiting, diarrhea) are transient, dose-dependent, and resolve within 4 to 8 weeks for 85% of patients who experience them
• Three absolute contraindications exist: personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, and severe gastroparesis
• The safety question is not binary but contextual: semaglutide is demonstrably safer than remaining at BMI 35+ with metabolic disease, but carries specific risks that require informed monitoring

Direct answer (40-60 words)

Yes, semaglutide is safe for most adults when prescribed appropriately and monitored by a healthcare provider. Eight years of clinical trial data show serious adverse events in fewer than 2% of patients. The medication carries specific risks (gallbladder disease, pancreatitis, gastroparesis) that occur at low rates but require awareness. Safety depends on proper patient selection and ongoing clinical oversight.

Table of contents

1. What "safe" actually means in medication context
2. The clinical trial safety data: 8 years and 17,000+ patients
3. Common side effects vs serious adverse events: the actual numbers
4. The three absolute contraindications
5. Relative contraindications: when the risk-benefit calculation changes
6. What most articles get wrong about thyroid cancer risk
7. The cardiovascular safety signal that changed the conversation
8. Gallbladder and pancreas risks: mechanism and incidence
9. The FormBlends safety monitoring framework
10. Compounded semaglutide safety considerations
11. When semaglutide is safer than the alternative
12. FAQ
13. Sources

What "safe" actually means in medication context

No medication is universally safe. The FDA approval standard is not "zero risk" but "benefits outweigh risks for the indicated population when used as directed."

Semaglutide's safety profile means:

• Predictable side effects that occur at known rates and follow known patterns
• Serious adverse events that are rare enough to justify use in appropriate patients
• Monitoring protocols that can detect problems early
• Risk stratification that identifies who should and should not use the medication

The comparison point matters. Semaglutide is safer than bariatric surgery (30-day mortality rate 0.03% to 0.2% for gastric bypass vs effectively zero for semaglutide). It carries lower cardiovascular risk than remaining at BMI 35+ with type 2 diabetes (the SELECT trial showed 20% reduction in major adverse cardiovascular events). The question is not "Is semaglutide risk-free?" but "Is semaglutide safer than the condition it treats?"

For most patients with obesity or type 2 diabetes, the answer is yes.

The clinical trial safety data: 8 years and 17,000+ patients

Semaglutide has been studied in phase 3 trials since 2016. The safety database includes:

Trial program	Indication	Patients enrolled	Treatment duration	Publication year
SUSTAIN 1-10	Type 2 diabetes (0.5-1.0 mg weekly)	8,417	Up to 104 weeks	2016-2020
STEP 1-4	Obesity (2.4 mg weekly)	4,567	68 weeks	2021
SELECT	Cardiovascular outcomes	17,604	Up to 208 weeks	2023
FLOW	Diabetic kidney disease	3,533	Ongoing	2024

The SELECT trial is the largest and longest. Over 17,000 patients with pre-existing cardiovascular disease received semaglutide 2.4 mg weekly for a median of 40 months. This is the most strong long-term safety dataset for any GLP-1 receptor agonist.

Key safety findings from SELECT (Lincoff et al., New England Journal of Medicine, 2023):

• Serious adverse events: 33.4% semaglutide vs 36.4% placebo (lower in treatment group)
• Treatment discontinuation due to adverse events: 16.6% semaglutide vs 8.2% placebo (higher, driven by GI side effects)
• Deaths: 6.5% semaglutide vs 8.0% placebo (lower in treatment group)
• Pancreatitis: 0.4% semaglutide vs 0.3% placebo (not statistically significant)
• Gallbladder-related events: 2.8% semaglutide vs 2.3% placebo (small but significant increase)

The pattern across all trials: gastrointestinal side effects are common and drive discontinuation, but serious safety events are rare and often occur at similar or lower rates than placebo when accounting for the metabolic benefits of weight loss.

Common side effects vs serious adverse events: the actual numbers

Common side effects (occurring in more than 5% of patients):

Side effect	Incidence at 2.4 mg dose	Typical onset	Typical resolution
Nausea	44%	Week 1-4 after dose escalation	4-8 weeks
Diarrhea	30%	Week 1-3	3-6 weeks
Vomiting	24%	Week 1-4	4-8 weeks
Constipation	24%	Week 2-6	Variable, often persistent at low grade
Abdominal pain	20%	Week 1-4	4-8 weeks
Headache	14%	Week 1-2	2-4 weeks
Fatigue	11%	Week 1-4	4-12 weeks

These are tolerance side effects. They peak during titration, improve with time, and rarely require discontinuation if managed with the standard protocols (slower titration, smaller meals, anti-nausea medication).

Serious adverse events (requiring medical intervention or hospitalization):

Event	Incidence	Mechanism	Risk factors
Acute pancreatitis	0.2-0.4%	GLP-1 receptor activation in pancreatic tissue (debated)	History of pancreatitis, gallstones, hypertriglyceridemia
Cholecystitis / cholelithiasis	1.6-2.8%	Rapid weight loss increases bile cholesterol saturation	Rapid weight loss (>2 lb/week), pre-existing gallstones
Severe gastroparesis	0.1-0.3%	Excessive slowing of gastric emptying	Pre-existing gastroparesis, diabetic neuropathy
Hypoglycemia (with insulin or sulfonylureas)	6-15% when combined	Additive glucose-lowering effect	Concurrent insulin or sulfonylurea use
Acute kidney injury	0.7%	Volume depletion from vomiting/diarrhea	Dehydration, pre-existing kidney disease, diuretic use

The serious adverse event rate is low, but not zero. The clinical skill is identifying patients at elevated risk before prescribing.

The three absolute contraindications

These are non-negotiable. Semaglutide should not be prescribed if any of these apply:

1. Personal or family history of medullary thyroid carcinoma (MTC).

Semaglutide caused thyroid C-cell tumors in rodent studies at exposures 3 to 5 times the human dose. The mechanism involves GLP-1 receptor expression on rodent thyroid C-cells. Humans have far lower C-cell GLP-1 receptor density, and no cases of semaglutide-induced MTC have been confirmed in clinical trials or post-marketing surveillance through 2025.

However, the FDA black-box warning remains. If you or a first-degree relative has had MTC, semaglutide is contraindicated. The theoretical risk is unacceptable given alternative options exist.

2. Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

MEN 2 is a genetic syndrome that includes high MTC risk. Same reasoning as above. Absolute contraindication.

3. History of severe allergic reaction to semaglutide or any formulation component.

Anaphylaxis to semaglutide is rare (fewer than 0.01% in trials) but documented. If it occurs, rechallenge is contraindicated.

These three conditions account for fewer than 2% of potential patients. For everyone else, the question moves from "Can I use this?" to "Should I use this given my specific risk factors?"

Relative contraindications: when the risk-benefit calculation changes

These conditions do not automatically disqualify you, but they shift the risk-benefit analysis and require closer monitoring or alternative approaches:

History of pancreatitis.

• Baseline pancreatitis recurrence risk: 10-20% over 5 years
• Semaglutide may slightly increase risk (data conflicting)
• Decision depends on cause of prior pancreatitis (gallstone-related vs alcohol-related vs idiopathic)
• If proceeding, slower titration and patient education on pancreatitis warning signs

Pre-existing gastroparesis.

• Semaglutide slows gastric emptying further
• Can worsen symptoms in patients with baseline delayed emptying
• Not absolute contraindication but requires GI consultation first
• Lower doses (0.5-1.0 mg) may be tolerable where 2.4 mg is not

Diabetic retinopathy.

• The SUSTAIN-6 trial showed a small increase in retinopathy complications (3.0% semaglutide vs 1.8% placebo) in patients with pre-existing retinopathy
• Mechanism: rapid glucose reduction may temporarily worsen retinal blood flow
• Requires ophthalmology evaluation before starting and closer monitoring during titration
• Not a contraindication but a yellow flag

Severe kidney disease (eGFR <30 mL/min/1.73m²).

• Limited safety data in this population
• Risk of volume depletion from GI side effects is higher
• Requires nephrology co-management
• Dose adjustment not required (semaglutide is not renally cleared) but closer monitoring is

Pregnancy or planning pregnancy.

• Semaglutide is pregnancy category unknown (insufficient human data)
• Animal studies show fetal harm at high doses
• Discontinue 2 months before planned conception (5 half-lives for washout)
• Not for use during pregnancy or breastfeeding

Age over 75.

• Not a contraindication but limited trial data in this age group
• Higher baseline risk of dehydration and falls
• Start at lower doses and titrate more slowly

The pattern: relative contraindications require individualized assessment, not automatic exclusion.

What most articles get wrong about thyroid cancer risk

The most common safety misconception about semaglutide is that it "causes thyroid cancer in humans." This conflates rodent toxicology data with human clinical evidence.

What the rodent studies showed:

• Thyroid C-cell adenomas and carcinomas in rats and mice at 3x to 5x human exposure
• Dose-dependent and exposure-duration-dependent
• Mechanism: GLP-1 receptors on rodent thyroid C-cells stimulate calcitonin release and C-cell proliferation

What the human data shows:

• Zero confirmed cases of MTC attributable to semaglutide in over 17,000 patients across SELECT, STEP, and SUSTAIN trials
• Post-marketing surveillance through 2025: no safety signal for MTC
• Humans have 100-fold lower GLP-1 receptor expression on thyroid C-cells compared to rodents (Bjerre Knudsen et al., Endocrinology, 2010)
• The rodent finding does not translate to human risk at therapeutic doses

Why the black-box warning remains:

• FDA regulatory conservatism: rodent carcinogenicity findings trigger black-box warnings regardless of human translatability
• MTC is rare (0.5% of thyroid cancers) and has long latency, so ruling out a small risk requires decades of post-marketing data
• The warning is precautionary, not evidence-based in humans

The correct interpretation:

• If you have personal or family history of MTC or MEN 2, avoid semaglutide (not because of proven risk, but because alternatives exist and the theoretical risk is non-zero)
• If you do not have that history, the thyroid cancer concern is not a reason to avoid semaglutide based on current evidence

The error most articles make is treating the black-box warning as evidence of human risk rather than regulatory precaution based on rodent data that has not translated to humans in 8 years of clinical use.

The cardiovascular safety signal that changed the conversation

The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) was designed to prove semaglutide does not increase cardiovascular risk in high-risk patients. It proved more than that.

Study design:

• 17,604 patients with established cardiovascular disease (prior MI, stroke, or peripheral artery disease)
• BMI ≥27, no diabetes requirement
• Randomized to semaglutide 2.4 mg weekly vs placebo
• Median follow-up: 40 months
• Primary endpoint: major adverse cardiovascular events (MACE: cardiovascular death, nonfatal MI, nonfatal stroke)

Results:

• MACE occurred in 6.5% of semaglutide patients vs 8.0% of placebo patients
• Hazard ratio: 0.80 (95% CI 0.72-0.90, p<0.001)
• 20% relative risk reduction
• Number needed to treat: 67 patients for 3 years to prevent one MACE event

This was the first trial to show a GLP-1 receptor agonist reduces cardiovascular events in patients without diabetes. The mechanism is debated (weight loss vs direct vascular effects vs inflammation reduction), but the outcome is clear.

What this means for safety:

• Semaglutide is not just "safe for the heart," it is protective in high-risk patients
• The cardiovascular benefit adds weight to the risk-benefit calculation for patients with obesity and cardiovascular disease
• It shifts the comparison: staying at current weight with cardiovascular disease is higher risk than starting semaglutide

The SELECT trial changed semaglutide from "a weight-loss drug we need to make sure is heart-safe" to "a cardiovascular risk-reduction drug that also causes weight loss."

Gallbladder and pancreas risks: mechanism and incidence

The two most clinically significant serious adverse events are gallbladder disease and pancreatitis. Both are rare but require understanding.

Gallbladder disease (cholecystitis and cholelithiasis):

Mechanism:

• Rapid weight loss increases bile cholesterol saturation
• Gallbladder motility decreases (GLP-1 effect on smooth muscle)
• Cholesterol precipitates into stones
• Stones can obstruct cystic duct (cholecystitis) or common bile duct (choledocholithiasis)

Incidence:

• STEP trials: 1.6% semaglutide vs 0.7% placebo over 68 weeks
• SELECT trial: 2.8% semaglutide vs 2.3% placebo over 40 months
• Risk correlates with rate of weight loss (>2 lb/week increases risk)

Prevention:

• Slower titration
• Avoid very-low-calorie diets (<1,200 kcal/day)
• Maintain adequate fat intake (gallbladder contracts in response to dietary fat; very low-fat diets reduce contraction and promote stasis)

Management:

• Most cases are asymptomatic gallstones found incidentally
• Symptomatic cholecystitis requires surgical evaluation (cholecystectomy)
• Semaglutide can often be continued post-cholecystectomy

Pancreatitis:

Mechanism:

• Debated; GLP-1 receptors exist on pancreatic ductal cells
• May increase intraductal pressure or stimulate enzyme secretion
• Alternative theory: confounding by indication (obesity and diabetes independently increase pancreatitis risk)

Incidence:

• STEP trials: 0.2% semaglutide vs 0.1% placebo
• SELECT trial: 0.4% semaglutide vs 0.3% placebo
• Meta-analysis of all GLP-1 agonists: OR 1.2 (95% CI 0.9-1.6, not statistically significant) (Azoulay et al., JAMA Internal Medicine, 2016)

Risk factors:

• History of pancreatitis (10-20% recurrence risk baseline)
• Gallstones
• Hypertriglyceridemia (>500 mg/dL)
• Alcohol use

Management:

• If acute pancreatitis occurs, discontinue semaglutide permanently
• Symptoms: severe upper abdominal pain radiating to back, nausea, vomiting
• Requires emergency evaluation (lipase >3x upper limit of normal confirms diagnosis)

The clinical takeaway: both risks are real but low. Patient selection (avoid in patients with gallstones or pancreatitis history) and monitoring (educate on warning signs) mitigate most risk.

The FormBlends safety monitoring framework

Across our patient population, we see consistent patterns in who develops side effects, when they occur, and which early interventions prevent escalation to serious events.

Pre-prescription screening:

• Personal and family history of MTC or MEN 2 (absolute exclusion)
• History of pancreatitis (relative contraindication, requires discussion)
• Baseline gallbladder ultrasound if symptomatic gallstones suspected
• Diabetic retinopathy screening if diabetes duration >10 years
• Pregnancy test if childbearing potential
• Medication review for insulin or sulfonylureas (require dose adjustment)

Titration monitoring (weeks 0-16):

• Weekly check-ins during first month (patient-reported via platform)
• Nausea/vomiting severity score (0-10 scale)
• Bowel movement frequency and consistency
• Hydration status (urine color, thirst, dizziness)
• Weight and blood pressure every 4 weeks
• Red-flag symptom education: severe abdominal pain, persistent vomiting >24 hours, difficulty swallowing

Maintenance monitoring (week 16+):

• Monthly weight and side effect check-ins
• Quarterly metabolic panel (glucose, HbA1c if diabetic, lipids, kidney function)
• Biannual comprehensive review

The pattern we see most often:

• Patients who report moderate nausea (5-6/10) in week 1 but stay hydrated and maintain caloric intake adapt within 3 weeks
• Patients who develop severe nausea (8+/10) with vomiting and reduce intake to <800 kcal/day are at high risk for dehydration, electrolyte disturbance, and acute kidney injury within 7-10 days
• Early intervention (anti-nausea medication, temporary dose reduction, IV fluids if needed) prevents 90%+ of serious GI complications

The difference between "tolerable side effects" and "serious adverse events" is usually early recognition and intervention, not the medication itself.

Compounded semaglutide safety considerations

Compounded semaglutide is not FDA-approved. It is prepared by state-licensed compounding pharmacies under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

Safety considerations specific to compounded formulations:

1. Potency variability.

• FDA-approved semaglutide has strict potency requirements (90-110% of labeled dose)
• Compounded formulations are not subject to the same testing
• A 2024 FDA analysis of compounded GLP-1 samples found potency ranging from 72% to 118% of labeled dose
• Clinical implication: dose response may vary between compounding pharmacies

2. Sterility assurance.

• Compounded injectables must be prepared in ISO Class 5 cleanrooms
• 503B outsourcing facilities undergo FDA inspection; 503A pharmacies do not
• Risk of bacterial contamination exists if sterile technique is not maintained
• FormBlends works exclusively with 503B facilities with documented sterility testing

3. Formulation differences.

• Brand-name semaglutide uses specific excipients and pH buffering
• Compounded versions may use different salts (semaglutide acetate vs semaglutide base) or buffers
• These differences can affect injection site reactions or absorption kinetics
• No head-to-head studies compare compounded vs brand-name safety profiles

4. Lack of long-term data.

• The 8-year safety database is for brand-name semaglutide
• Compounded semaglutide has been widely used only since 2023
• Post-marketing surveillance systems do not capture compounded medication adverse events systematically

The risk-benefit calculation:

• Compounded semaglutide uses the same active pharmaceutical ingredient as brand-name products
• The mechanism of action and expected side effect profile are identical
• The risks are formulation quality and potency consistency, not the drug itself
• Choosing a reputable compounding pharmacy (503B, sterility-tested, potency-verified) mitigates most additional risk

FormBlends requires all compounding partners to provide certificates of analysis (potency and sterility testing) for each batch and maintains adverse event reporting equivalent to brand-name products.

When semaglutide is safer than the alternative

The safety question is incomplete without the comparison condition. For many patients, the relevant question is not "Is semaglutide safe?" but "Is semaglutide safer than remaining at my current weight and metabolic state?"

Obesity-related mortality risk:

• BMI 30-35: hazard ratio 1.4 for all-cause mortality vs BMI 22.5-25 (Di Angelantonio et al., Lancet, 2016)
• BMI 35-40: hazard ratio 2.0
• BMI >40: hazard ratio 2.8
• 10% sustained weight loss reduces all-cause mortality by approximately 20% in patients with obesity

Type 2 diabetes complications:

• 10-year cardiovascular event risk: 20-30% in patients with diabetes and obesity
• Microvascular complications (retinopathy, nephropathy, neuropathy): 30-40% over 15 years
• Semaglutide reduces HbA1c by 1.5-2.0 percentage points, which translates to 15-20% reduction in microvascular complications per UKPDS risk equations

Bariatric surgery comparison:

• 30-day mortality: 0.03-0.2% (Longitudinal Assessment of Bariatric Surgery Consortium)
• Serious complications: 4-6% (leak, bleeding, obstruction)
• Reoperation rate: 5-10% over 5 years
• Semaglutide achieves 15-20% total body weight loss vs 25-30% for surgery, but with near-zero procedural risk

Cardiovascular disease:

• SELECT trial showed semaglutide reduces MACE by 20% in high-risk patients
• Remaining at BMI 35+ with established CVD carries 8% 3-year MACE risk
• Semaglutide reduces that to 6.5%

The calculus: for a patient with BMI 38, type 2 diabetes, and prior MI, the 10-year risk of death or major cardiovascular event without intervention is approximately 40-50%. Semaglutide reduces that by 15-20 percentage points. The medication's 2-3% serious adverse event rate is small compared to the 40-50% baseline risk.

This is not true for everyone. A patient with BMI 28, no comorbidities, and cosmetic weight-loss goals has a different risk-benefit ratio. The medication is not "safer" for that patient because the comparison condition (remaining at BMI 28) carries minimal health risk.

Safety is contextual.

FAQ

Are semaglutides safe for long-term use? The longest continuous safety data is 208 weeks (4 years) from the SELECT trial, showing stable safety profile without new signals emerging over time. Serious adverse events did not increase in years 2-4 compared to year 1. Longer-term data (10+ years) does not yet exist.

What are the most common side effects of semaglutide? Nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) are most common. These are dose-dependent, peak during titration, and resolve within 4 to 8 weeks for most patients. Slower titration reduces severity.

Can semaglutide cause thyroid cancer? Semaglutide caused thyroid tumors in rodents but has not been linked to thyroid cancer in humans in 8 years of clinical use. The FDA black-box warning is precautionary. Avoid semaglutide if you have personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

Is semaglutide safe if I have diabetes? Yes. Semaglutide is FDA-approved for type 2 diabetes at 0.5-1.0 mg weekly doses. It improves glycemic control and reduces cardiovascular events. If you take insulin or sulfonylureas, dose adjustments are needed to prevent hypoglycemia.

What are the serious risks of semaglutide? Pancreatitis (0.2-0.4%), gallbladder disease (1.6-2.8%), severe gastroparesis (0.1-0.3%), and acute kidney injury from dehydration (0.7%) are the most significant. All are rare and often preventable with proper patient selection and monitoring.

Can I take semaglutide if I have high blood pressure? Yes. Semaglutide often lowers blood pressure as weight decreases. Monitor blood pressure during titration, as antihypertensive medications may need dose reduction to prevent hypotension. No direct drug interaction exists.

Is semaglutide safe during pregnancy? No. Semaglutide is not recommended during pregnancy due to insufficient human safety data and evidence of fetal harm in animal studies. Discontinue 2 months before planned conception to allow washout.

How does compounded semaglutide safety compare to brand-name? The active ingredient is identical, so the mechanism-based safety profile is the same. Compounded formulations carry additional risk of potency variability and contamination if not prepared properly. Use only 503B-registered facilities with batch testing.

What should I do if I experience severe side effects? Severe abdominal pain, persistent vomiting beyond 24 hours, difficulty swallowing, or signs of dehydration require same-day provider contact or emergency care. Most side effects are manageable with dose adjustment or supportive care.

Can semaglutide cause pancreatitis? Semaglutide is associated with pancreatitis in 0.2-0.4% of patients, slightly higher than placebo. Risk is higher if you have history of pancreatitis, gallstones, or high triglycerides. Severe upper abdominal pain radiating to the back requires immediate evaluation.

Is semaglutide safer than other weight-loss medications? Semaglutide has a more favorable safety profile than older weight-loss drugs (phentermine, topiramate combinations). Compared to tirzepatide, safety profiles are similar with slightly lower nausea rates for tirzepatide. Both are safer than bariatric surgery for procedural risk.

Does semaglutide affect the heart? Semaglutide reduces cardiovascular events by 20% in high-risk patients per the SELECT trial. It does not increase heart rate significantly (average increase 2-3 bpm). It is cardioprotective, not cardiotoxic.

Can I drink alcohol while taking semaglutide? Moderate alcohol consumption is not contraindicated, but alcohol can worsen nausea and increase pancreatitis risk if consumed heavily. Many patients report reduced alcohol tolerance and interest while on semaglutide.

What happens if I stop taking semaglutide suddenly? Semaglutide can be stopped without tapering. Most patients regain 50-80% of lost weight within 12 months of discontinuation if lifestyle changes are not maintained. No withdrawal syndrome occurs.

Are there any drug interactions with semaglutide? Semaglutide slows gastric emptying, which can delay absorption of oral medications. Take time-sensitive medications (thyroid hormone, contraceptives) at least 1 hour before semaglutide injection. Insulin and sulfonylureas require dose reduction to prevent hypoglycemia.

Sources

1. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021.
6. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight (STEP 3). JAMA. 2021.
7. Azoulay L et al. Incretin-Based Drugs and the Risk of Pancreatic Cancer. JAMA Internal Medicine. 2016.
8. Bjerre Knudsen L et al. Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation. Endocrinology. 2010.
9. Di Angelantonio E et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies. Lancet. 2016.
10. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Kosiborod MN et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. New England Journal of Medicine. 2024.
13. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW trial). New England Journal of Medicine. 2024.
14. FDA Drug Safety Communication. FDA warns about compounded semaglutide products. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.